Compare Gartner Inc (IT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Organon & Co. Common Stock — how do they compare? Gartner Inc trades at $197.78 (market cap $12.44B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Gartner Inc is far larger — about 3.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Gartner Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 65 Days and Organon & Co. Common Stock for 0 Days on average.
| IT | OGN | |
|---|---|---|
Market Cap | $12.44B | $3.62B |
Volume | 818,587 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $258.17 | $13.81 |
52-Week Low | $125.68 | $5.70 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $14.18B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner Inc. (IT) trades at $195.77, up 0.86% on the day, with a bullish technical signal and strong profitability metrics including a 69.63% gross margin and 113.58% ROE. Recent earnings beats and positive news flow around AI advisory demand support the stock, though net cash flow turned negative in 2025. The current price sits above the consensus target of $178.14, indicating potential overvaluation concerns among analysts.
Outlook remains positive due to robust contract value growth and AI-driven demand, but risks include volatile cash flows, high P/B ratio of 160.06, and a shareholder investigation. Investor sentiment is mixed with 55.55% hold ratings, suggesting cautious optimism amid execution risks and macroeconomic uncertainty.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
